Vancouver, British Columbia — February 20, 2026 — Leads & Copy —
DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) has signed a Letter of Intent with Hanson Instruments Ltd., trading as Hanson Medical, to explore a commercial partnership for the TeaRx™ dry-eye diagnostic platform in the UK. The exploration will be exclusive until May 15, 2026.
Hanson Medical, established in 1996, supplies ophthalmic and optometric equipment across the UK, Europe, and the US. The LOI will allow Hanson Medical to evaluate the market and engage with eye-care professionals in the UK to assess clinical integration, commercial demand, and adoption of TeaRx™.
TeaRx™ is a CE-IVD-approved diagnostic solution that analyzes tear fluid to provide clinicians with data for diagnosing and managing dry eye disease. It aims to reduce reliance on complex techniques and enable faster clinical decisions.
During the LOI period, DiagnosTear and Hanson Medical will collaborate to determine the most effective commercialization route in the UK, including distribution, pricing, and clinical engagement programs. A definitive commercial agreement may follow, pending the results of the LOI period and mutual approval.
Dr. Shimon Gross, CEO of DiagnosTear, said the UK is a sophisticated ophthalmic market. He added that working with Hanson Medical will allow DiagnosTear to assess workflow integration and lay the groundwork for market development.
DiagnosTear continues to expand its commercial footprint through partnerships that combine local market expertise with the company’s tear-based diagnostic platform. The UK initiative supports European growth and strengthens DiagnosTear’s position in ocular diagnostics.
DiagnosTear Technologies Inc. develops point-of-care diagnostics for ocular diseases, providing insights based on tear-fluid analysis, with the goal of transforming ophthalmic care through accessible diagnostics.
Source: DiagnosTear Technologies Inc.
